Global PNH and aHUS Market Growth (Status and Outlook) 2023-2029

Global PNH and aHUS Market Growth (Status and Outlook) 2023-2029

PNH and aHUS, both are extremely rare and genetic diseases. Due to PNH, destruction of red blood cells of a person occurs quite sooner than it should. It is an acquired hematopoietic stem cell disorder. Hematopoietic stem cells are developed in bone marrow and eventually turn into red blood cells, white blood cells and platelets. A person with PNH has some defected hematopoietic cells which create defective red blood cells. These defective cells are highly susceptible to premature destruction by the complement system. aHUS is a disorders in which blood clots are formed in small blood vessels throughout the body. TMA can lead to heart stroke, attack, kidney failure and death.
LPI (LP Information)' newest research report, the “PNH and aHUS Industry Forecast” looks at past sales and reviews total world PNH and aHUS sales in 2022, providing a comprehensive analysis by region and market sector of projected PNH and aHUS sales for 2023 through 2029. With PNH and aHUS sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PNH and aHUS industry.
This Insight Report provides a comprehensive analysis of the global PNH and aHUS landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PNH and aHUS portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PNH and aHUS market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PNH and aHUS and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PNH and aHUS.
The global PNH and aHUS market size is projected to grow from US$ 5039.2 million in 2022 to US$ 7902.7 million in 2029; it is expected to grow at a CAGR of 6.6% from 2023 to 2029.
United States is the largest consumption place, with a consumption market share nearly 52.1% in 2019. Following United States, Europe is the second largest consumption place with the consumption market share of 26.2%.
This report presents a comprehensive overview, market shares, and growth opportunities of PNH and aHUS market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Soliris
Ultomiris
Segmentation by application
PNH
aHUS
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Alexion Pharmaceuticals
Alnylam Pharmaceuticals
Omeros Corporation

Please note: The report will take approximately 2 business days to prepare and deliver.